WO2007136614A3 - Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel - Google Patents

Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel Download PDF

Info

Publication number
WO2007136614A3
WO2007136614A3 PCT/US2007/011594 US2007011594W WO2007136614A3 WO 2007136614 A3 WO2007136614 A3 WO 2007136614A3 US 2007011594 W US2007011594 W US 2007011594W WO 2007136614 A3 WO2007136614 A3 WO 2007136614A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
progression
assays
diagnosis
Prior art date
Application number
PCT/US2007/011594
Other languages
French (fr)
Other versions
WO2007136614A2 (en
Inventor
Viswanath Devanarayan
Vijay Modur
Jeffrey L Seeburger
Gary J Romano
Adam J Simon
Wesley K Tanaka
Omar Laterza
Original Assignee
Merck & Co Inc
Viswanath Devanarayan
Vijay Modur
Jeffrey L Seeburger
Gary J Romano
Adam J Simon
Wesley K Tanaka
Omar Laterza
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Viswanath Devanarayan, Vijay Modur, Jeffrey L Seeburger, Gary J Romano, Adam J Simon, Wesley K Tanaka, Omar Laterza filed Critical Merck & Co Inc
Publication of WO2007136614A2 publication Critical patent/WO2007136614A2/en
Publication of WO2007136614A3 publication Critical patent/WO2007136614A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Databases & Information Systems (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a novel and sensitive means of monitoring Alzheimer's disease. The method consists of the construction of statistically relevant multi-analyte panels, through the use of shrunken centroids (SC), simulated annealing algorithm (SAA) and genetic algorithm (GA) within the framework of linear discriminant analysis (LDA) or through the use of random forest (RF) analysis of individual biomarkers, to more accurately and objectively assess the status of an individual for the purposes of disease classification and predicting cognitive endpoints such as MMSE, CAMCOG, or Learning Memory, a subscore of CAMCOG.
PCT/US2007/011594 2006-05-19 2007-05-15 Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel WO2007136614A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80196206P 2006-05-19 2006-05-19
US60/801,962 2006-05-19
US90039607P 2007-02-09 2007-02-09
US60/900,396 2007-02-09

Publications (2)

Publication Number Publication Date
WO2007136614A2 WO2007136614A2 (en) 2007-11-29
WO2007136614A3 true WO2007136614A3 (en) 2008-10-30

Family

ID=38723795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011594 WO2007136614A2 (en) 2006-05-19 2007-05-15 Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel

Country Status (1)

Country Link
WO (1) WO2007136614A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094315A1 (en) * 2008-12-09 2012-04-19 Stephanie Fryar-Williams Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US20140086836A1 (en) * 2011-05-03 2014-03-27 Mental Health Research Institute Method for detection of a neurological disease
CN106202984B (en) * 2016-08-26 2018-09-04 赵毅 It is a kind of based on multilayer complex network to the screening technique of tumour miRNA marker
CN108256422B (en) * 2017-12-07 2021-11-09 广东技术师范大学 Alzheimer disease classification method, system and device based on Gaussian process classification
CN108256423B (en) * 2017-12-07 2021-11-16 广东技术师范大学 Alzheimer disease feature extraction method and system based on overall correlation coefficient

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601985A (en) * 1991-08-14 1997-02-11 Trustees Of The Univ. Of Pennsylvania Method of detecting abnormally phosphorylated tau(τ)
US6465195B2 (en) * 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
US20050244890A1 (en) * 2003-11-07 2005-11-03 Davies Huw A Biomarkers for Alzheimer's disease
US20050256397A1 (en) * 2002-03-20 2005-11-17 Mony De Leon Csf biomarker dilution factor corrections by mri imaging and algorithm

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5601985A (en) * 1991-08-14 1997-02-11 Trustees Of The Univ. Of Pennsylvania Method of detecting abnormally phosphorylated tau(τ)
US6465195B2 (en) * 1999-12-30 2002-10-15 Washington University Predictive diagnostic for Alzheimer's disease
US20050256397A1 (en) * 2002-03-20 2005-11-17 Mony De Leon Csf biomarker dilution factor corrections by mri imaging and algorithm
US20050244890A1 (en) * 2003-11-07 2005-11-03 Davies Huw A Biomarkers for Alzheimer's disease

Also Published As

Publication number Publication date
WO2007136614A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2007136614A3 (en) Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel
WO2008039996A3 (en) Multi-detector gas identification system
WO2005017646A3 (en) System, software and methods for biomarker identification
MX2020004617A (en) Cardiovascular risk event prediction and uses thereof.
WO2006121952A3 (en) Diagnostic biomarkers for neurodevelopmental disorders
WO2011038155A3 (en) Genetic analysis
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2007076523A3 (en) Markers and methods for assessing and treating psoriasis and related disorders
WO2005079332A3 (en) Display enhanced testing for concussions and mild traumatic brain injury
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
WO2008039918A3 (en) Methods and apparatus for hybrid outlier detection
EP2963129A3 (en) Autism associated genetic markers
ATE512365T1 (en) MAP-2 PROTEOLYTIC PRODUCTS AS DIAGNOSTIC BIOMARKERS FOR NEURAL INJURY
WO2014071358A3 (en) Novel ntrk1 fusion molecules and uses thereof
WO2007041134A3 (en) Computer method and system for predicting physical properties using a conceptual segment model
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
EP4306955A3 (en) Integrated functional and molecular profiling of cells
WO2007047408A3 (en) Promac signature application
WO2006007479A3 (en) Method for enumerating mammalian cell micronuclei via differential staining
WO2015056091A3 (en) Assessment system
WO2008028031A3 (en) Markers and methods for assessing and treating ulcerative colitis and related disorders using a 43 gene panel
WO2008048508A3 (en) Prognostic biomarkers in patients with ovarian cancer
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
NZ609824A (en) Immunochromatography devices, methods and kits

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07809080

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07809080

Country of ref document: EP

Kind code of ref document: A2